Adaptive BiotechnologiesNASDAQ: ADPT

More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers

Adaptive Biotechnologies Corporation (ADPT) Q4 2023 Earnings Call Transcript

SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Adaptive Biotechnologies offers services related to immunosequencing and immune medicine. Genius Sports' sports data and technology is used by more than 400 sports organizations worldwide.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Tycho Peterson - CFO Nitin Sood - Chief Commercial Officer, MRD Susan Bobulsky - Senior Vice President, Diagnostics, clonoSEQ Sharon Benzeno - Chief Commercial Officer, Immune Medicine Conference Call Participants Mark Massaro - BTIG Dan Brennan - TD Cowen David Westenberg - Piper Sandler Operator Thank you for standing by. At this time, I would like to welcome everyone to today's Adaptive Biotechnologies 2023 Third Quarter Earnings Call.

After a number of updates, there is no change in my investment rating for Adaptive Biotechnologies Corporation. Q2 FY'23 results showed mixed performance, with expectations for FY'23 sales to hit $215mm at the upper end of guidance. Technical indicators suggest a neutral posture for ADPT in the coming months.

Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Investing in biotech stocks is challenging even when you're investing in established companies with commercially available drugs and expansive pipelines. And investing in up-and-coming biotech stocks is only for the most risk-tolerant investors.

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.